BioSpace News Archive

Liquid biopsies are thought to have many advantages over tumor biopsies.

The event attracts research innovators and business professionals who wish to learn about advanced technologies being developed at the National Cancer Institute (NCI) and Frederick National Laboratory (FNL).

Narayan is a senior scientist and group lead at the Center for Molecular Microscopy.

As a deadly mystery disease with an unknown etiology caused worldwide panic in the early 1980s and quickly became an epidemic, Dr. Jeffrey Lifson was right in the middle of it.

In 1981, Dr. Edgar Engleman, an immunologist and Director of the Stanford Blood Center learned of two patients that had been admitted to Stanford Hospital with a new disease.

More than 20 abstracts by FNL investigators will be presented in mini symposia, late-breaking research and poster sessions throughout the March 29 to April 3 meeting at the Georgia World Congress Center.

Drs. Dmitrovsky, Sharpless, and Lowy contend that the Frederick National Laboratory is a little-known entity to the cancer research community, but it “could be a great part of its discovery arsenal.”

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced interim data from Study 206, its Phase 2 basket clinical trial of reloxaliase, an orally-administered, recombinant oxalate-degrading enzyme.

ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the successful completion of its single ascending dose (SAD) study testing the first-in-class therapeutic antibody ASLAN004 in healthy volunteers, and the updated data from the second part of the study that tested a subcutaneous formulation of ASLAN004.